Drug Research
Boehringer Ingelheim and Eli Lilly company plans to conduct Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
New studies will evaluate the effect of JARDIANCE for the treatment of chronic heart failure There are approximately 26 million people worldwide, and 5.7 million people in the U.S., suffering from chronic heart failure The studies build...
Drug Research
Baxter announced the launch of a ready-to-use VANCOMYCIN Injection in sodium chloride for US
Only Manufacturer to Offer the Antibiotic in a Ready-to-Use Premixed Presentation World pharma today/Press releases /-Advancing Baxter’s longstanding commitment to provide hospitals with convenient presentations of medications that drive efficiency during drug preparation and enhance patient...
Articles
Top 5 Ways to Avoid Drug Errors
Every month millions of Americans pick up their prescription at the pharmacy, only to discover that their pill looks different than the month before. Last month’s oval, white pills embossed with “3972V” are now round, and display imprint “ML24”....
Articles
The Specialty Pharmacy: A One-to-One Personalized Approach
Maybe you’ve noticed: medications are getting more complicated, more personalized, and more expensive.
Look at some of the recent drugs approved for cancer, hepatitis C virus, or rheumatoid arthritis. These are three very different conditions, but many newer drugs used...
Articles
Diabetes Symptoms & Complications
Symptoms
People with type 1 or type 2 diabetes may have a range of symptoms. These symptoms might include:
Frequent urination (polyuria) -- often at night (nocturia)
Excessive thirst (polydipsia)
Extreme hunger (polyphagia)
Dry skin
Weakness/feeling tired much of the...
Articles
Diabetes Risk Factors & Prevention
Risk Factors
Risk factors are characteristics that can predispose you to developing a condition or disease. Just because you have one or more risk factors does not mean you will get diabetes. Risk factors for type 1 diabetes are not...
Drug Research
Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT (Amphetamine Extended-Release Orally Disintegrating Tablet) for ADHD
Neos Therapeutics, Inc, a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD) announced that the U.S. FDA approved Adzenys XR-ODT for the treatment of ADHD in patients six...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















